Subscribe
brexit_istock-531915594_altamira83
altamira83 / iStockphoto.com
19 November 2018Big Pharma

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

The UK has an excellent opportunity to adopt laws on supplementary protection certificates (SPCs) that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
LSPN Europe 2018: Chinese filings impressive statement, says EPO director
15 November 2018   Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.
Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Asia-Pacific
LSPN Europe 2018: Chinese filings impressive statement, says EPO director
15 November 2018   Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.

More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Asia-Pacific
LSPN Europe 2018: Chinese filings impressive statement, says EPO director
15 November 2018   Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility